rs2919872 — FABP1 FABP1 Promoter Variant

FABP1 rs2919872 — Your Liver's Fatty Acid Traffic Controller

Deep in chromosome 2, about 2,000 base pairs before the FABP1 gene begins, sits a single nucleotide change that determines how actively your liver produces its primary fatty acid shuttle protein. FABP1 — Fatty Acid Binding Protein 1, also called L-FABP (liver FABP) — is the most abundant intracellular fatty acid binding protein in the liver¹¹ FABP1 — Fatty Acid Binding Protein 1, also called L-FABP (liver FABP) — is the most abundant intracellular fatty acid binding protein in the liver
FABP1 constitutes approximately 3–5% of all cytosolic protein in human hepatocytes; it is also expressed in the small intestine and kidney at lower levels. Your hepatocytes use FABP1 to grab long-chain fatty acids as they enter from the portal circulation, shuttle them through the cytoplasm, and deliver them to mitochondria, peroxisomes, and the endoplasmic reticulum for beta-oxidation, phospholipid synthesis, or assembly into triglycerides for VLDL export. The rs2919872 promoter variant determines how much of this protein gets made — and in turn how efficiently your liver processes dietary fat.

The Mechanism

The FABP1 gene sits on the minus (complementary) strand of chromosome 2. The rs2919872 variant is located in the promoter region approximately 2 kb upstream of the transcription start site. In the plus-strand genome reference this is a C→T substitution; in coding-strand notation (as used in most papers) this corresponds to G→A.

A 2015 functional study in human liver cell lines²² A 2015 functional study in human liver cell lines
Peng et al. 2015, PLoS One, n=1,182 healthy Chinese volunteers directly tested both alleles in a promoter-reporter assay and found that the A allele (T on plus strand) "dramatically decreased the FABP1 promoter activity" compared to the G allele (C on plus strand). This reduced transcription produces measurably lower serum FABP1 protein: the study reported GG homozygotes averaging 13.67 ± 2.60 ng/mL serum FABP1, GA heterozygotes 9.44 ± 2.29 ng/mL, and AA homozygotes just 5.13 ± 4.38 ng/mL (P < 0.01) — a gradient of roughly 30% reduction per risk allele.

The lower FABP1 expression in T allele carriers mirrors what is seen in mouse genetics: mice with targeted deletion of the Fabp1 gene show markedly impaired hepatic long-chain fatty acid uptake during fasting³³ mice with targeted deletion of the Fabp1 gene show markedly impaired hepatic long-chain fatty acid uptake during fasting
Newberry et al. 2003, J Biol Chem — L-FABP null mice showed only a 2-fold vs 10-fold increase in hepatic TG during 48h fasting, with reduced fatty acid incorporation into triglycerides and diacylglycerols. The human variant is a milder, dose-dependent version of this same phenotype.

The Evidence

In the same 1,182-person Chinese cohort, the A allele (T on plus strand) was significantly associated with lower serum triglycerides (P = 0.032) after adjusting for age, sex, BMI, and lifestyle factors. This appears paradoxical — reduced FABP1 might be expected to impair hepatic TG clearance — but is consistent with the mouse data showing that FABP1-deficient livers accumulate less TG during fasting (through reduced fatty acid uptake) while also secreting less VLDL-TG into the bloodstream.

A contrasting picture emerged from a 2023 Polish case-control study examining hypercholesterolemia⁴⁴ 2023 Polish case-control study examining hypercholesterolemia
Świderska et al. 2023, Pol Arch Intern Med, n=360 (109 hypercholesterolemia, 251 controls): the CC genotype was over 2.5-fold less likely to be diagnosed with hypercholesterolemia than T allele carriers (OR = 0.386; 95% CI 0.203–0.735; P = 0.003). No association was found with serum lipid concentrations directly, suggesting the CC genotype may protect through mechanisms not captured by a single fasting lipid panel — possibly through more efficient hepatic LDL-cholesterol uptake and processing enabled by intact FABP1 expression.

The strongest GWAS signal connects rs2919872 to serum alkaline phosphatase (ALP), a marker of hepatocyte and biliary function. Multiple large GWAS show the T allele significantly lowers ALP (p = 6.0 × 10⁻²⁸; β = −0.0195), consistent with reduced FABP1 expression impairing the full metabolic function of hepatocytes. Given that FABP1 handles not only fatty acids but also bilirubin, bile acids, and certain drugs within the liver, lower FABP1 expression plausibly reduces the overall metabolic throughput of hepatocytes.

Evidence from a related FABP1 variant (rs2241883, the T94A missense variant) extends the clinical picture: in 553 Chinese NAFLD patients vs 553 controls⁵⁵ in 553 Chinese NAFLD patients vs 553 controls
Peng et al. 2012, Gene, the FABP1 C allele of rs2241883 was associated with OR = 1.32 for NAFLD, with cumulative risk when combined with a second FABP1 intronic variant. A comprehensive review further documented that FABP1 variants are associated with elevated plasma TG and LDL, altered BMI, atherothrombotic stroke, and NAFLD through endocannabinoid system alterations: Schroeder et al. 2016, Lipids⁶⁶ Schroeder et al. 2016, Lipids.

Practical Actions

For CT and TT carriers, the implication is an FABP1 system running below full capacity. Hepatic fatty acid uptake and processing is moderately to substantially impaired, with downstream effects on lipid handling. Monitoring fasting lipid panels (particularly LDL and non-HDL cholesterol), liver function tests, and — for TT homozygotes — markers of liver health is warranted.

Because the variant affects hepatic fat transport rather than dietary fat absorption, dietary changes that reduce the hepatic fat load are the most mechanistically targeted intervention: reducing saturated fat intake shifts the quality of fatty acids the liver must process, and limiting dietary cholesterol directly reduces the LDL-related risk associated with lower FABP1.

Interactions

rs2919872 functions in the same gene as rs2241883 (T94A, the coding variant in FABP1 exon 3) and rs2197076 (an intronic FABP1 variant). Carrying risk alleles at multiple FABP1 loci compounds the overall impairment of hepatic fatty acid handling; the 2012 NAFLD study showed additive risk when two FABP1 variants were combined. These SNPs likely tag distinct functional elements — promoter activity (rs2919872), protein function (rs2241883), and splicing/ expression (rs2197076) — and may be partially independent.